Abstracts tagged "anti-TNF therapy"

Abstract Number: 1818 • 2012 ACR/ARHP Annual Meeting
Latent Tuberculosis Detection and Tuberculosis Reactivation in Patients Receiving Anti-TNFá Drugs: A Nationwide Italian Survey
Fabrizio Cantini¹, Ennio Lubrano², Alessandro Mathieu³, Antonio Marchesoni⁴, Carlo Salvarani⁵, Raffaele Scarpa⁶ and Antonio Spadaro⁷, ¹U.O.C. Reumatologia, Prato Hospital, Prato, Italy, ²Cattedra di Reumatologia, Università del Molise, Campobasso, Italy, ³Unit and Chair of Rheumatology, University Hospital of Cagliari, Cagliari, Italy, ⁴Rheumatology, Istituto Ortopedico Gaetano Pini, Milano, Italy, ⁵Rheumatology, Arcispedale S Maria Nuova-IRCCS, Reggio Emilia, Italy, ⁶c/o Medical University, Via Pansini 5, Naples, Italy, ⁷Cattedra di Reumatologia, Univeristà La Sapienza di Roma, Roma, Italy
Background/Purpose: Anti-TNFα drugs are associated with an increased risk of tuberculosis (TB) and several recommendation sets for latent tubercular infection (LTBI) detection and TB reactivation…
Abstract Number: 1215 • 2012 ACR/ARHP Annual Meeting
Rates of Orthopaedic Interventions for Rheumatoid Arthritis Have Changed Over the Last 25 Years. A Report From Two UK Inception Cohorts Reflecting Treatment Changes From Sequential DMARD Monotherapy to Anti-TNF Agents (1986-2011)
Elena Nikiphorou¹, Lewis Carpenter², Sam Norton³, David James⁴, Patrick D. Kiely⁵, David Walsh⁶, Richard Williams⁷ and Adam Young³, ¹Research Department of Epidemiology & Public Health, UCL and Rheumatology, St Albans City Hospital, ERAS, St Albans City Hospital and University College London (UCL), London, United Kingdom, ²Centre for Lifespan & Chronic Illness Research, University of Hertfordshire, Hatfield, United Kingdom, ³Rheumatology, ERAS, St Albans City Hospital, St Albans, United Kingdom, ⁴Rheumatology, Diana Princess of Wales Hospital, Grimsby, United Kingdom, ⁵Rheumatology Dept, St. Georges Hospital, London, United Kingdom, ⁶Academic Rheum/Clin Sci Bldg, City Hospital, Nottingham, United Kingdom, ⁷Rheumatology, County Hospital, Hereford, United Kingdom
Background/Purpose: Orthopaedic surgery is considered an important, although uncommonly reported, outcome measure in rheumatoid arthritis (RA) and a surrogate marker for joint destruction. The expectation…
Abstract Number: 492 • 2012 ACR/ARHP Annual Meeting
Divergent Toxicity of TNF Inhibitors On Demyelinating Disorders and Neurological Events
Sergio Schwartzman¹, John Clark² and John J. Cush³, ¹Rheumatology, Hosp for Special Surgery, New York, NY, ²RiskBenefits LLC, Flourtown, PA, PA, ³Baylor Research Institute, Dallas, TX
Background/Purpose: There are currently five anti-TNF agents that have been approved for various autoimmune illnesses. There is no convincing evidence that any one of these…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.